IFM Special: MLR-90™ Metabolic-Liver Reset Package

Metabolic-Liver Reset Protocol (MLR-90)

A structured 90-day program that combines objective cardiometabolic testing, targeted supplementation, and guided lifestyle intervention into one repeatable clinical framework.

The MLR-90 is built around a simple but clinically powerful premise: measure first, intervene with precision, measure again. The protocol opens with a baseline CMiQ DBS Test Kit, establishing an objective Physiologic Strain Model snapshot across cardiometabolic and hepatic domains including the Fatty Liver Index. Your patient then follows a 90-day structured program anchored by Bergacyn supplementation, guided nutrition, and interval walking training. At the end of the protocol, a second CMiQ DBS Test Kit documents the physiologic shift. Progress is visible in data, not patient self-report.

Why BergaPure®️

BergaPure®️ aka Bergacyn (distributed by DolCas Biotech, Landing NJ) is a patented combination of bergamot polyphenolic fraction and wild cardoon extract. It is the specific formulation studied in the Ferro et al. (2020) randomized, double-blind, placebo-controlled trial published in Frontiers in Endocrinology, on which the MLR-90 protocol is directly modeled. The MLR-90 uses one Bergacyn capsule daily, delivering the same active ingredient content administered in that trial.

In the Ferro et al. trial, 102 non-diabetic adults with confirmed hepatic steatosis received either Bergacyn or placebo once daily for 12 weeks, alongside Mediterranean dietary guidance. Key findings in the Bergacyn group included:

• Liver fat reduction nearly double that of placebo as measured by controlled attenuation parameter (CAP) score: a mean reduction of 48.2 dB/m vs. 26.9 dB/m in the placebo group (p = 0.02)
• Strongest and most direct hepatic effect in adults over 50: a 15% CAP score reduction that remained statistically significant after adjustment for weight loss, indicating a direct hepatic mechanism beyond caloric deficit alone (p = 0.007)
• 78% of participants over 50 showed measurable improvement in liver steatosis grade vs. 44% in the placebo group
• Significantly greater body weight reduction vs. placebo: 4.2 kg vs. 2.7 kg (p = 0.004), with 49% of the Bergacyn group losing more than 4 kg compared to 22% in the placebo group
• Within-group improvements in LDL cholesterol, total cholesterol, non-HDL cholesterol, HOMA-IR, AST, ALT, and GGT in the Bergacyn group, all reaching statistical significance within the treatment arm

The dual-ingredient mechanism is clinically relevant. Bergamot polyphenols act via lipophagy stimulation, HMG-CoA reductase inhibition, and mitochondrial pathway modulation to reduce hepatic fat accumulation and support lipid metabolism. Wild cardoon contributes choleretic, anti-inflammatory, and anti-hyperlipidemic properties through cynaropicrin, its primary active sesquiterpene. The combination addresses hepatic steatosis through complementary pathways that neither ingredient covers alone.

The MLR-90 pairs Bergacyn with interval walking training, a structured approach to moderate-intensity exercise that is well-tolerated in the target patient population and supported by evidence for improving insulin sensitivity, hepatic lipid clearance, and cardiometabolic markers. The combination of targeted supplementation and structured movement is designed to produce additive physiologic benefit that is fully documented by the CMiQ testing bookends.

Ideal Patient Profile

The MLR-90 is designed for non-diabetic patients who present with early-to-moderate physiologic strain across cardiometabolic and hepatic domains, including one or more of the following patterns:

• Elevated Fatty Liver Index with or without confirmed hepatic steatosis
• Insulin resistance or impaired fasting glucose patterns
• Atherogenic dyslipidemia: elevated TG, low HDL, elevated AIP, ApoB, Lp(a) or TyG index
• Elevated hsCRP or GGT indicating inflammatory or hepatic strain
• Overweight or android obesity pattern, particularly in patients over 50 years where the hepatic effect of Bergacyn was most pronounced in the clinical trial
• Patients motivated to make measurable, documented change with a structured, supervised program

What's Included

The Core Advantage

Most metabolic programs rely on recommendations and patient self-report. The MLR-90 replaces subjective assessment with objective before-and-after data. The CMiQ Physiologic Strain Model scores at baseline and at 90 days give both practitioner and patient a clear, visual record of what changed and by how much. That documentation supports ongoing patient engagement, reinforces protocol adherence, and gives practitioners a repeatable revenue-generating framework built on measurable clinical outcomes.

For licensed practitioners only. Not intended to diagnose, treat, cure, or prevent disease. Individual results will vary. Clinical findings referenced are from Ferro Y et al. (2020), Frontiers in Endocrinology, and pertain to the Bergacyn formulation used in that study. Results should be interpreted within the context of a complete professional clinical evaluation.